Qualitative disorders of platelets and megakaryocytes

被引:90
作者
Nurden, AT [1 ]
机构
[1] CHU Bordeaux, Inst Federatif Rech 4, Pessac, France
关键词
activation pathways; gene therapy; inherited disorder; integrin; megakaryocyte; platelet;
D O I
10.1111/j.1538-7836.2005.01428.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Qualitative disorders of platelet function and production form a large group of rare diseases which cover a multitude of genetic defects that by and large have as a common symptom, excessive mucocutaneous bleeding. Glanzmann thrombasthenia, is enabling us to learn much about the pathophysiology of integrins and of how alpha IIb beta 3 functions. Bernard-Soulier syndrome, an example of macro-thrombocytopenia, combines the production of large platelets with a deficit or non-functioning of the major adhesion receptor of platelets, the GPIb-IX-V complex. Amino acid substitutions in GPIb alpha, may lead to up-regulation and spontaneous binding of von Willebrand factor as in Platelet-type von Willebrand disease. In disorders with defects in the MYH9 gene, macrothrombocytopenias are linked to modifications in kidney, eye or ear, whereas other inherited thrombocytopenias variously link a low platelet count with a propensity to leukemia, skeletal defects, learning impairment, and abnormal red cells. Defects of secretion from platelets include an abnormal alpha-granule formation as in the gray platelet syndrome (with marrow myelofibrosis), and of organelle biogenesis in the Hermansky Pudlak and Chediak-Higashi syndromes where platelet dense body defects are linked to abnormalities of other lysosomal-like organelles including melanosomes. Finally, defects involving surface receptors (P2Y(12), TP alpha) for activating stimuli, of proteins essential for signaling pathways (including Wiskott-Aldrich syndrome), and of platelet-derived procoagulant activity (Scott syndrome) show how studies on platelet disorders are helping unravel the pathways of primary hemostasis.
引用
收藏
页码:1773 / 1782
页数:10
相关论文
共 100 条
[1]   Factor XI interacts with the leucine-rich repeats of glycoprotein Ibα on the activated platelet [J].
Baglia, FA ;
Shrimpton, CN ;
Emsley, J ;
Kitagawa, K ;
Ruggeri, ZM ;
López, JA ;
Walsh, PN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) :49323-49329
[2]   Effects of the R216Q mutation of GATA-I on erythropoiesis and megakaryocytopoiesis [J].
Balduini, CL ;
Pecci, A ;
Loffredo, G ;
Izzo, P ;
Noris, P ;
Grosso, M ;
Bergamaschi, G ;
Rosti, V ;
Magrini, U ;
Ceresa, IF ;
Conti, V ;
Poggi, V ;
Savoia, A .
THROMBOSIS AND HAEMOSTASIS, 2004, 91 (01) :129-140
[3]  
Balduini CL, 2003, HAEMATOLOGICA, V88, P582
[4]   c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia [J].
Ballmaier, M ;
Germeshausen, M ;
Schulze, H ;
Cherkaoui, K ;
Lang, S ;
Gaudig, A ;
Krukemeier, S ;
Eilers, M ;
Strauss, G ;
Welte, K .
BLOOD, 2001, 97 (01) :139-146
[5]  
Ballmaier M, 1998, Stem Cells, V16 Suppl 2, P177
[6]   Anti-GPVI-associated ITP:: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRγ-chain complex from the human platelet surface [J].
Boylan, B ;
Chen, H ;
Rathore, V ;
Paddock, C ;
Salacz, M ;
Friedman, KD ;
Curtis, BR ;
Stapleton, M ;
Newman, DK ;
Kahn, ML ;
Newman, PJ .
BLOOD, 2004, 104 (05) :1350-1355
[7]  
BRETONGORIUS J, 1981, AM J PATHOL, V102, P10
[8]   Probing platelet factor 4 α-granule targeting [J].
Briquet-Laugier, V ;
Lavenu-Bombled, C ;
Schmitt, A ;
Leboeuf, M ;
Uzan, G ;
Dubart-Kupperschmitt, A ;
Rosa, JP .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (12) :2231-2240
[9]   Mechanisms of WASp-mediated hematologic and immunologic disease [J].
Burns, S ;
Cory, GO ;
Vainchenker, W ;
Thrasher, AJ .
BLOOD, 2004, 104 (12) :3454-3462
[10]   Inherited platelet-based bleeding disorders [J].
Cattaneo, M .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (07) :1628-1636